Anti-Suicide Drugs Market – Global Industry Insights, Trends And Opportunity Analysis, 2014-2024

Artificial Pancreas Market Industry
ANTI-SUICIDE DRUGS MARKET - GLOBAL INDUSTRY
INSIGHTS, TRENDS AND OPPORTUNITY ANALYSIS,
2016-2024
[DATE]
[COMPANY NAME]
[Company address]
Report Description
Suicidal thoughts have many causative factors such as depression, no hope in life, substance abuse,
post-traumatic stress disorder, bipolar disorder, or financial crisis. Moreover, suicides may be the result of
side effects from drugs such as anti-depressants, an overdose of opioids. Treatment for suicidal thoughts
includes psychotherapy, medications, addiction treatment, and family support. Medications include
antidepressants, anti-anxiety medications, antipsychotic medications, and other medications for mental
illness. These medications will only help to reduce the symptoms of suicidal thoughts. Addiction treatment
which includes detoxification, self-help group meetings and addiction treatment programs may also help
in alleviating the thoughts of suicide.
Increasing Incidences of Suicides Globally
Globally, the World Health Organization (WHO) estimates that over 800,000 people die to suicide every
year. When it comes to regional analysis the scenario doesn’t differ much based on the economic status
of the country. Suicidal attempts are the highest in emerging nations in Asia, Africa and Eastern Europe
followed by the Latina America, the U.S., Australia and some European countries. According to the
Centers for Disease Control and Prevention (CDC) estimate, more than 9 million people in the United
States reported having suicidal thoughts in 2013. The suicide rates in the country have been increasing
according to the American Foundation for Suicide Prevention, reaching a suicide rate of 12.93 per 1,000
populations in 2014.
Get more information @ https://www.coherentmarketinsights.com/ongoing-insight/anti-suicidedrugs-market-10
New Treatment Options under Research
Lack of an effective and focused therapy for suicidal attempts is compelling the use of alternative, less
effective and unapproved therapies. Researchers are in an endeavor to find an effective therapeutic
solution to this perilous condition. A recent study published in the American Journal of Psychiatry,
demonstrated the benefits of administering buprenorphine in curbing the suicidal thoughts after one week
of the trial. Anti-depressants and some anti-psychotic medications take longer time to be effective in curing
suicidal thoughts. The drug could become the first fast-acting anti-suicide drug in future studies also result
with similar findings as in this preliminary study. Although use of opioids also carries a risk of suicidal
thoughts and attempts, buprenorphine has the lowest risk amongst the drugs in this class.
Another study from NeuroRx, an Israeli based life science startup found the molecule D -cycloserine and
effective treatment option for depression and suicide. D-cycloserine is a N-methyl-D-aspartate (NMDA)
antagonist. The drug has shown to reduce the symptoms within two hours of treatment in it Phase 2 trails.
Moreover, the positive outcomes were observed to lasts for over eight weeks. The company also found
that use of combination therapy which includes ketamine, D-cycloserine and one of three FDA-approved
mood stabilizer is much more effective than ketamine alone which is also used by many doctors to treat
acute depression. The company expects a fast track approval process for this drug from the U.S. FDA
once the clinical trials are completed by the end of 2017.
Ask for Table of Content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/10
There is a Dire Need for an Effective and Targeted Drug
Suicide is viewed as an end stage of depression, whereas it is a distinct medical condition that needs
special attention. The current market for the treatment of suicide is a subset of the drugs used to treat
anxiety and depression. A fast track approval of the drug D-cycloserine will help address this unmet
medical condition. A recent study carried out by the Nordic Cochrane Centre, with 70 trials involving
18,000 people found that antidepressants doubled the risk of suicide and aggressive behavior in people
under the age of 18 years. Therefore, there is dire need for targeted and effective drug to treat suicides.
About Us
COMPANY OVERVIEW
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting
our plethora of clients achieve transformational growth by helping them make critical business decisions.
We are headquartered in India, having office at global financial capital in the U.S. Our client base includes
players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to
help businesses around the globe deliver practical and lasting results through various recommendations
about operational improvements, technologies, emerging market trends and new working methods. We
offer both customized and syndicated market research reports that help our clients create visionary growth
plans to provide traction to their business. We meticulously study emerging trends across various
industries at both the global and regional levels to identify new opportunities for our clientele. Our global
team of over 100 research analysts and freelance consultants provide market intelligence from the very
molecular country level and also provide a global perspective of the market. Our team is of the most vital
cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive
defusion training module.This allows for an objective and unbiased assessment of the market. We pride
ourselves in my constantly striving to update our extremely in-depth understanding of the market by
closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable
industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize
on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth
path in the future.
Contact Us
CORPORATE OFFICE:
Coherent Market Insights
303, Astral Court,Above Reliance Fresh,
Near Gaikwad Petrol Pump,
Aundh, Pune – 411045, India
sales@coherentmarketinsights.com

Suicide is viewed as an end stage of depression, whereas it is a distinct medical condition that needs special attention. The current market for the treatment of suicide is a subset of the drugs used to treat anxiety and depression. A fast track approval of the drug D-cycloserine will help address this unmet medical condition. A recent study carried out by the Nordic Cochrane Centre, with 70 trials involving 18,000 people found that antidepressants doubled the risk of suicide and aggressive behavior in people under the age of 18 years. Therefore, there is dire need for targeted and effective drug to treat suicides.

Download Report